tiprankstipranks
Advertisement
Advertisement
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development
PremiumCompany AnnouncementsTvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development
2M ago
Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
Premium
The Fly
Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
2M ago
Tvardi Therapeutics price target lowered to $4 from $5 at Barclays
Premium
The Fly
Tvardi Therapeutics price target lowered to $4 from $5 at Barclays
2M ago
Tvardi Therapeutics updates STAT3 fibrosis-focused clinical pipeline
PremiumCompany AnnouncementsTvardi Therapeutics updates STAT3 fibrosis-focused clinical pipeline
5M ago
Tvardi Therapeutics announces further Phase 2 REVERT IPF data
Premium
The Fly
Tvardi Therapeutics announces further Phase 2 REVERT IPF data
5M ago
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario
Premium
Ratings
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario
6M ago
Tvardi Therapeutics’ Liver Cancer Study: A Potential Game-Changer?
PremiumCompany AnnouncementsTvardi Therapeutics’ Liver Cancer Study: A Potential Game-Changer?
7M ago
Tvardi downgraded to Market Perform from Outperform at Raymond James
Premium
The Fly
Tvardi downgraded to Market Perform from Outperform at Raymond James
8M ago
Tvardi Therapeutics Faces Setback in Phase 2 Trial
Premium
Company Announcements
Tvardi Therapeutics Faces Setback in Phase 2 Trial
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100